Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cardiff OncologySTU:XE7C -2.14%37 EV-to-FCF is -0.54 as of Jul. 24, 2026. GuruFocus rates STU:XE7C with a GF Score™ of 37/100. The stock has 4 warning signs investors should review. Among 340 Biotechnology companies, Cardiff Oncology ranks worse than 294117.35% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cardiff Oncology's Enterprise Value is €17.36 Mil.
Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-32.18 Mil. Therefore, Cardiff Oncology's EV-to-FCF for today is -0.54.
The historical rank and industry rank for Cardiff Oncology's EV-to-FCF or its related term are showing as below:
STU:XE7C'
s EV-to-FCF Range Over the Past 10 Years
Min: -33.33 Med: -0.68 Max: 2.57
Current: -0.53
During the past 13 years, the highest EV-to-FCF of Cardiff Oncology was 2.57. The lowest was -33.33. And the median was -0.68.
STU:XE7C's EV-to-FCF is ranked worse than 100% of 340
companies
in the Biotechnology industry
Industry Median: 14.79
vs STU:XE7C: -0.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cardiff Oncology's PE Ratio (TTM) for today is calculated as:
Cardiff Oncology's share price for today is €0.731.
Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.577.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cardiff Oncology EV-to-FCF Related Terms
Cardiff Oncology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:XE7C vs MAIA, TELO, OSTX: EV-to-FCF Comparison
For the Biotechnology subindustry, Cardiff Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's EV-to-FCF falls into.
Cardiff Oncology's current Enterprise Value is €17.36 Mil.
Cardiff Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-32.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (STU:XE7C) has a EV-to-FCF of -0.54 as of Jul. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cardiff Oncology and its competitors. According to the industry distribution chart, Cardiff Oncology ranks #999999 out of 340 companies in the Biotechnology industry.
Is Cardiff Oncology's EV-to-FCF too high?
Cardiff Oncology's current EV-to-FCF is -0.54. Based on the distribution chart, Cardiff Oncology ranks #999999 out of 340 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cardiff Oncology has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's EV-to-FCF compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #999999 out of 340 companies for EV-to-FCF. This places Cardiff Oncology in the lower half of its industry. The industry median EV-to-FCF is 14.79. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.79, based on 340 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current EV-to-FCF is -0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (STU:XE7C) has a current EV-to-FCF of -0.54. The current EV-to-FCF is -0.54. Cardiff Oncology's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cardiff Oncology (STU:XE7C), the current EV-to-FCF is -0.54 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
37GF Score
Get the complete analysis for STU:XE7C
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XE7C has been successfully added to your 
